BIOMAT Database Logo BIOMAT Database Logo

Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. 2008

Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
Wills Eye Institute, Philadelphia, Pennsylvania, USA.

OBJECTIVE To evaluate same-day combination intravitreal bevacizumab/panretinal photocoagulation (PRP) for the treatment of neovascular glaucoma (NVG) compared with PRP alone. METHODS This was an institutional review board-approved, retrospective, consecutive case-control study of patients receiving same-day combination bevacizumab/PRP or PRP alone as treatment of NVG from September 2004 through June 2007. Visual acuity, intraocular pressure (IOP), presence of anterior segment neovascularization, and required glaucoma interventional procedures were recorded. RESULTS A total of 23 patients were identified, 11 in the bevacizumab/PRP group and 12 in the PRP alone group. The bevacizumab/PRP group had a significant reduction in IOP compared with the PRP alone group (-11 vs. 0 mmHg, respectively; P = 0.03). There was a significantly higher frequency and rate of neovascular regression in the combination therapy group than in the PRP only group (11 vs 2 eyes [P < 0.001] and 12 vs 127 days [P < 0.0001], respectively). Average follow-up was 143 days for the bevacizumab/PRP group and 118 days for the PRP alone group. CONCLUSIONS Combination treatment resulted in more rapid decrease in IOP. In addition, the combination group had increased frequency and rapidity of regression of neovascularization. This study provides a foundation for further research and suggests consideration for a possible new paradigm for the treatment of NVG.

UI MeSH Term Description Entries
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D007429 Intraocular Pressure The pressure of the fluids in the eye. Ocular Tension,Intraocular Pressures,Ocular Tensions,Pressure, Intraocular,Pressures, Intraocular,Tension, Ocular,Tensions, Ocular
D008297 Male Males
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068258 Bevacizumab An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS. Avastin,Bevacizumab-awwb,Mvasi,Bevacizumab awwb

Related Publications

Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
Panretinal Photocoagulation Plus Intravitreal Bevacizumab Versus Panretinal Photocoagulation Alone for Proliferative Diabetic Retinopathy.
December 2018, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma.
January 2009, European journal of ophthalmology,
Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.
May 2013, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma.
May 2009, Optometry (St. Louis, Mo.),
Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma.
December 2013, Journal of glaucoma,
Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C.
December 2010, Journal of glaucoma,
Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy.
January 2017, Pakistan journal of medical sciences,
Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy.
January 2016, International journal of ophthalmology,
Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy.
January 2020, Arquivos brasileiros de oftalmologia,
Justis P Ehlers, and Marc J Spirn, and Andrew Lam, and Arunan Sivalingam, and Michael A Samuel, and William Tasman
Intravitreal Bevacizumab Alone Versus Intravitreal Bevacizumab In Combination With Focal Macular Photocoagulation In Diabetic Macular Oedema.
January 2022, Journal of Ayub Medical College, Abbottabad : JAMC,
Copied contents to your clipboard!